The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Clovis Oncology (Inst); Genzyme (Inst); Lilly (Inst)
Consulting or Advisory Role - QED Therapeutics
Research Funding - Clovis Oncology (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); Genzyme (Inst); Lilly (Inst); Pfizer (Inst)
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
 
Chung-Han Lee
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
James J Hsieh
Consulting or Advisory Role - Eisai
Research Funding - BostonGene
 
Arpit Rao
No Relationships to Disclose
 
Alvaro Pinto
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Allen Lee Cohn
Honoraria - Bristol-Myers Squibb; Ipsen
Speakers' Bureau - Bristol-Myers Squibb; Ipsen
 
Christopher Di Simone
No Relationships to Disclose
 
David R. Shaffer
No Relationships to Disclose
 
Regina Girones Sarrio
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Pfizer; Roche; Sanofi
Speakers' Bureau - Abbott; Acraf; Bristol-Myers Squibb; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Abbott; Acraf; Pfizer; Roche; Sanofi
 
Sara Gunnestad Ribe
Stock and Other Ownership Interests - Nordic Nanovector (I)
 
Jane Wu
Employment - Eisai
 
Emmett V. Schmidt
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Peter Kubiak
Employment - Eisai
Stock and Other Ownership Interests - Apyx Medical; ImmunoGen; Mallinckrodt; Seres Therapeutics; Sesen Bio; ZIOPHARM Oncology
 
Alan D. Smith
Employment - Eisai
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)